Prevymis (letermovir) - Merck (MSD)
Optimizing CMV prevention after allogenic hematopoietic stem cell transplantation: using CMV-specific cellular immunity to guide letermovir prophylaxis. (PubMed, Blood Sci) - Dec 24, 2025 - No abstract available 
Journal • Bone Marrow Transplantation • Transplantation
http://www.ncbi.nlm.nih.gov/pubmed/41438869
 
Sisi Zhen; Sizhou Feng; Xin Chen
 
Dec 24, 2025
 
Prev Next